Top Markets
Coin of the day
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd.

CANF
Classificação em ações #40868
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical... Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.
Preço da ação
$1.63
Valor de mercado
$70.02K
Variação (1 dia)
-2.11%
Variação (1 ano)
-81.59%
País
IL
Negociar Can-Fite BioPharma Ltd. (CANF)

Categoria

Rácio P/B de Can-Fite BioPharma Ltd. (CANF)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Can-Fite BioPharma Ltd., o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da Can-Fite BioPharma Ltd. de 2026 a 2026
Rácio P/B no final de cada ano
Ano Rácio P/B Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/B de empresas semelhantes ou concorrentes
Empresa Rácio P/B Diferença do rácio P/B País
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE